ImmunityBio’s (IBRX) Buy Rating Reiterated at D. Boral Capital
D. Boral Capital restated their buy rating on shares of ImmunityBio (NASDAQ:IBRX – Free Report) in a report released on Friday,Benzinga reports. They currently have a $30.00 price target on the stock. Several other analysts have also issued reports on the company. BTIG Research initiated coverage on ImmunityBio in a report on Friday, January 10th. […]
D. Boral Capital restated their buy rating on shares of ImmunityBio (NASDAQ:IBRX – Free Report) in a report released on Friday,Benzinga reports. They currently have a $30.00 price target on the stock. Several other analysts have also issued reports on the company. BTIG Research initiated coverage on ImmunityBio in a report on Friday, January 10th. […]
